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a b s t r a c t
The presence of amyloid aggregates of human islet amyloid polypeptide (hIAPP), a hallmark of type
2 diabetes, contributes to pancreatic β-cell impairment, where oxidative stress plays a key role.
A contribution of NADPH oxidase to reactive oxygen species (ROS) generation after cell exposure to
micromolar concentrations of hIAPP aggregates has been suggested. However, little is known about
β-cells exposure to lower amounts of hIAPP aggregates, similar to those found in human pancreas.
Thus, we aimed to investigate the events resulting from RIN-5F cells exposure to nanomolar concentra-
tions of toxic hIAPP aggregates. We found an early and transient rise of NADPH oxidase activity resulting
from increased Nox1 expression following the engagement of receptor for advanced glycation end-
products (RAGE) by hIAPP aggregates. Unexpectedly, NADPH oxidase activation was not accompanied by
a significant ROS increase and the lipoperoxidation level was significantly reduced. Indeed, cell exposure
to hIAPP aggregates affected the antioxidant defences, inducing a significant increase of the expression
and activity of catalase and glutathione peroxidase. We conclude that exposure of pancreatic β-cells to
nanomolar concentrations of hIAPP aggregates for a short time induces an hormetic response via the
RAGE-Nox1 axis; the latter stimulates the enzymatic antioxidant defences that preserve the cells against
oxidative stress damage.
& 2013 The Authors. Published by Elsevier B.V. All rights reserved.
Introduction
hIAPP is a peptide hormone co-secreted with insulin by
pancreatic β-cells with a glucomodulatory role in animal metabo-
lism [1]. The presence of fibrillar deposits of hIAPP amyloid
aggregates in the islets of Langerhans is a recognised hallmark of
type 2 diabetes which is strongly related to pancreatic β-cell
sufferance and death, a fundamental feature of the disease [2,3].
hIAPP fibrillar aggregates result from peptide misfolding, possibly
favoured by the presence of lipid membranes or other biological
surfaces, with structural reorganisation into early unstable oligo-
meric assemblies displaying a strong tendency to interact with the
cell surface [4,5]. Amyloid oligomers further grow into increasingly
ordered polymers eventually generating straight, unbranched,
6–10 nm wide, several μm long, β-structure enriched fibrils [6].
Growing evidence suggests that oxidative stress plays a key
role in the onset of type 2 diabetes [7]. In addition, β-cells express
low physiological levels of the antioxidant enzymes superoxide
dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx)
[8,9]. Many sources of ROS contributing to the development of
type 2 diabetes have been described: a high level of mitochondrial
oxidative phosphorylation, glucose auto-oxidation, production of
Advanced Glycation End products (AGEs), overexposure to Angio-
tensin II (which increases NADPH oxidase activity) [10,11] and cell
exposure to hIAPP aggregates which induce some alteration of
membrane permeability [10,12]. The importance of ROS increase
as a cause of cell sufferance during exposure to high concentra-
tions of hIAPP aggregates has been indirectly confirmed by the
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protection provided by antioxidants; the latter were found to
improve the viability of either RINm5F β-cells and INS-1E β-cells
exposed to 10 μM hIAPP aggregates [13] and to 10–30 μM hIAPP
aggregates [14], respectively.
A problem with in vitro studies is that usually hIAPP doses are
far from those normally found in the human pancreas; in fact,
hIAPP can reach a millimolar concentration inside intracellular
storage granules [15] but it is rapidly diluted outside the cell
reaching picomolar concentrations in the plasma [16]. So, even
though a local increase of hIAPP concentration in the islets can be
postulated in the context of amyloid aggregation, it is hard to
accept that it could reach micromolar levels. Then, we aimed to
investigate the molecular and cellular events associated with the
exposure of RIN-5F β-cells to nanomolar concentrations of hIAPP
aggregates. In particular, we were interested in assessing the
contribution of NADPH oxidase as a source of ROS at these
experimental conditions, since its involvement in oxidative stress
in cells exposed to 10–30 μM hIAPP had already been suggested
[12].
NADPH oxidase is an ubiquitous multi-subunit enzyme which
generates superoxide from molecular oxygen using NADPH as the
electron donor. NADPH oxidase was originally identified in pha-
gocytes, where it consists of two membrane-associated subunits,
p22phox and gp91phox (renamed Nox2), and at least four cytosolic
subunits (p47phox, p67phox, p40phox and Rac1/2), which translocate
to the membrane upon enzyme activation. Seven isoforms of the
catalytic subunit Nox (Nox1-5, Duox 1 and 2), with different
cellular localisation, tissue distribution and expression are known
[17–19]. The RINm5F pancreatic β-cells (of which RIN-5F is a
subclone) express only Nox1 and Nox4 [20]. Nox4 is constitutively
expressed and active, whereas Nox1, like the Nox2 isoform,
requires other components for activity. In fact, Nox1 is constitu-
tively associated with NoxO1 and NoxA1, the p47phox and p67phox
homologues, respectively [19].
In this study we report the effect of cell exposure to low
concentrations of hIAPP aggregates for short time periods. Our
results led us to uncover an unexpected hormetic effect of such
treatment that involved NADPH oxidase activation via RAGE yet
resulting in cell protection against oxidative stress through a
significant increase of the enzymatic antioxidant defences.
Material and methods
Cell culture
Rat RIN-5F insulinoma cells, from American Type Culture Collec-
tion (ATCC), were cultured as described previously [21].
Production of hIAPP amyloid aggregates
hIAPP (Calbiochem, La Jolla, CA) was dissolved in 80% hexa-
fluoroisopropanol (HFIP, Sigma-Aldrich, Steinheim, Germany) to a
concentration of 512 μM and stored at 20 1C until use. hIAPP
aggregates were prepared by diluting hIAPP to 6.5 μM in 10 mM
phosphate buffer, pH 7.4, 1.0% HFIP, and by incubating the mixture
at 25 1C for 30 min [21]. Aggregate morphology was determined
by Transmission Electron Microscopy (TEM) as previously
described [21]. rIAPP (Bachem, Bubendorf, Switzerland) was dis-
solved and incubated at the same conditions as hIAPP.
Cell treatments
Freshly prepared hIAPP aggregates were diluted in cell culture
medium without phenol red, containing 0.5% FCS, and adminis-
tered to RIN-5F cells. Cells were also treated with similarly diluted
rIAPP. In some experiments, the cells were pre-treated for 1 h with
(i) the NADPH oxidase inhibitors diphenyleneiodonium (DPI,10 μM)
and apocynin (Apo,100 μM); (ii) a blocking anti-RAGE antibody (sc-
5563, Santa Cruz Biotech), 20 μg/mL; (iii) the CAT and GPx inhibitors
3-amino-1,2,4-triazole (ATZ) and mercaptosuccinic acid (MS) (20 mM
and 7.0 mM, respectively) [22]. All inhibitors were from Sigma.
Experiments were carried out to optimise inhibitor concentrations.
Cell viability assessment
20,000 cells/well were seeded into 96-well plates in complete
medium, cultured for 48 h and then treated for 3 h with hIAPP
aggregates diluted to 60 nM (here and thereafter, aggregate con-
centration refers to the monomeric peptide concentration).
Cell viability was determined by the 3-(4,5-dimethyl-2-thiazolyl)-
2,5-diphenyl-2H-tetrazolium bromide (MTT) assay as previously
described [21]; cell mortality was assessed by determining the
Lactate Dehydrogenase (LDH) release in the culture medium with
the CytoTox-ONE™ Homogeneous Membrane Integrity Assay (Pro-
mega, Italy) [23].
NADPH oxidase activity determination by lucigenin
chemiluminescence
The cells were treated with 60 nM hIAPP aggregates for 0–4.5 h
and with 60, 120 or 500 nM hIAPP, or with 120 nM rIAPP for 3.0 h.
After washing twice with PBS, the cells were harvested, incubated
for 60 min in 20 mM ice-cold Tris–HCl buffer, pH 7.4, containing
10 μg/ml leupeptin, 10 μg/ml aprotinin, 1.0 mM PMSF and phos-
phatase inhibitors (Sigma, Italy) and sonicated to obtain total cell
lysates. Protein concentration was determined by the bicinchoni-
nic acid (BCA) protein assay (Pierce, Italy). Superoxide generation
was assayed at room temperature using lucigenin (5.0 μM)-
enhanced chemiluminescence, as previously described [24].
Each measurement was performed in 20 mM Tris HCl, pH 7.4 with
30–60 μg of total cell lysate proteins in the absence or in the
presence of specific oxidase substrates (300 μM NADPH for
NADPH oxidase, 5.0 mM succinate for mitochondrial oxidase
complex I or 1.0 mM xanthine for xanthine oxidase). Further
measurements were performed after the addition of the NADPH
oxidase inhibitors DPI (20 μM) and Apo (100 μM). A buffer blank
was subtracted from each reading. Superoxide production was
detected using a Lumat LB 9507 luminometer (EG&G Berthold)
and calculated as an arbitrary light unit (MLU) over 10 min.
Intracellular ROS content and lipid peroxidation assay
Intracellular ROS content was measured by monitoring the
oxidation of 2',7'-dihydrodichlorofluorescein diacetate (H2DCF-DA,
Invitrogen, Italy) to the fluorescent dichlorofluorescein (DCF),
as previously described [25]. The cells were treated with 10 μM
H2DCF-DA for 10 min before the end of a 3.0 h exposure to 60 nM
hIAPP. After washing twice with PBS, the cells were lysed in RIPA
buffer (50 mM Tris /HCl buffer, pH 7.5 containing 150 mM NaCl,
2.0 mM EGTA, 100 mM NaF, 2.0% Triton X-100, 1.0 mM vanadate,
0.1% SDS, 2.0 mM EDTA, 2.0 mM PMSF, 10 μg/ml leupeptin, and
10 μg/ml aprotinin). DCF fluorescence was measured on a Fluor-
oskan Ascent Fluorometer (Thermo Electron Corporation, Finland),
and normalised to the total protein content. Lipid peroxidation
was evaluated as malonyldialdehyde (MDA) content using a
“Bioxytech LPO-586 Assay” kit (Oxis International Inc., Prodotti
Gianni, Italy), according to the manufacturer instructions.
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Antioxidant enzyme activities
Total cell lysates were spun at 1500g at 4 1C for 10 min and
70 μg of supernatant proteins were used to determine antioxidant
enzyme activities.
CAT activity assay
The samples were diluted in 100 mM phosphate buffer, pH 6.8,
containing 10 mM H2O2. CAT activity as μmol/min/mg of protein
was determined as previously described [26].
GPx activity assay
The samples were diluted in 100 mM phosphate buffer, pH 7.4,
containing 0.5 mM EDTA, 1.0 mM NaN3, 0.25 mM NADPH,
2.25 mM GSH, 1.0 U/ml glutathione reductase. After addition of
0.24 mM t-butyl hydroperoxide (Sigma, Italy), the change of the
optical density of NADPH was monitored at 340 nm for 2.0 min at
25 1C [27] and GPx activity, as nmol/min/mg of protein, was
calculated.
SOD activity assay
SOD activity was evaluated using a Chemical Superoxide Dis-
mutase Assay kit (Cayman Chemical, Ann Arbour, MI, USA) as
previously described [27] and calculated as U/mg protein.
Western blotting
The cells were lysed directly in Laemmli buffer (66 mM Tris–
HCl, pH 6.8, 2% (w/v) SDS, 10 mM EDTA, 10% (w/v) glycerol), boiled
for 10 min and clarified at 10,000g for 10 min. Equal protein
amounts were separated on 12% SDS-PAGE and transferred to
PVDF membranes (Amersham Bioscience, UK). After blocking with
5.0% (w/v) BSA in 0.1% (v/v) PBS-Tween-20, the membranes were
incubated overnight at 4 1C with goat anti-Nox1 (1:500, sc-25545),
goat anti-Nox4 (1:1000, ab109225), rabbit anti-RAGE (1:500),
rabbit anti-CAT (1:1000, sc-50508) and rabbit anti-GPx (1:1000,
sc-30147) antibodies. Following 1.0 h incubation with donkey anti-
goat (1:10,000, sc-2020) or goat anti-rabbit (1:10, 000, sc-2004)
secondary antibodies, the immunoreactive bands were detected by
the chemiluminescent Immobilon Western HRP Substrate (Milli-
pore, MA, USA) and quantified by densitometric analysis using a
ChemiDoc system and the Quantity One software (Bio-RAD
Laboratories, Italy). Rabbit anti-GAPDH (1:5000, sc-25778) was
used as a reference for equal protein loading. Anti-Nox4 was from
Abcam (Cambridge, U.K.), all other antibodies were from Santa
Cruz Biotech (Santa Cruz, CA, USA).
Statistical analysis
All data (average of three determinations for each sample) were
converted into percentages of the maximum value for each experi-
ment and reported as mean7SD from at least three independent
experiments. Statistical analysis of the data was performed using
the Tukey–Kramer test. Differences were considered significant at
the po0.05 level.
Results
NADPH oxidase activity in RIN-5F cells
Many data support the idea that, similarly to amyloid oligomers of
other peptides and proteins, hIAPP pre-fibrillar aggregates are also
cytotoxic [28,29] and that a derangement of the redox status does
occur in exposed cells, although recent evidence suggests that the
ability of hIAPP fibrils to distort and disassemble the cell membrane
is also an important feature of oligomer toxicity [30,31]. We used
throughout the study early hIAPP aggregates obtained by incubating
the peptide for 30 min in aggregation-promoting conditions and
whose structure and toxicity were previously characterised exten-
sively by Thioflavine-T assay, CD, FTIR, MTT assay and caspase-3
activity assay [21]. Aggregates were freshly prepared immediately
before their administration to cells and TEM analysis confirmed that
mature fibrils were not present (Fig. 1). Due to their extreme dilution,
it was not possible to perform structural analysis on hIAPP aggregates
at the end of the incubation in cell culture, anyway, their interaction
with cells in these conditions was previously demonstrated by
immunofluorescence analysis [21].
Considering that most studies on hIAPP cytotoxicity were
carried out at quite harsh conditions (micromolar concentrations
of peptide, long times of cell exposure), the aim of our study was
to assess the effect of quite milder, more physiological, conditions
on the redox status and viability of cultured RIN-5F pancreatic
cells. At first we wanted to determine the contribution of the
various enzymatic sources of superoxide in RIN-5F cells. We found
a significant superoxide increase in cells, with respect to the basal
level measured in the absence of substrates, only in the presence
of NADPH (48.04712.01 MLU/s Vs 16.9770.66 MLU/s, po0.0001,
N¼10), whereas superoxide production was negligible in the
presence of succinate (16.0970.67 MLU/s, N¼10) or xanthine
(17.3873.11 MLU/s, N¼10), suggesting that NADPH oxidase was
likely a major source of superoxide in these cells. Then, we
investigated whether NADPH oxidase was involved in the mole-
cular events following cell exposure to nanomolar concentrations
of hIAPP aggregates. NADPH -dependent superoxide production
was significantly higher in cells exposed for 3.0 h to 60 nM hIAPP
aggregates (po0.001), as compared to cells exposed to vehicle
(t0 value, Fig. 2A). On the contrary, when the cells were exposed
for 3.0 h to higher hIAPP concentrations, NADPH oxidase activation
was substantially unchanged up to 120 nM hIAPP and declined to
the level of vehicle-treated cells at 500 nM hIAPP (Fig. 2B). For this
reason, all subsequent investigations were carried out by treating
the cells for 3.0 h with 60 nM hIAPP. No significant effect on
NADPH oxidase activity was observed in cells exposed for 3.0 h to
120 nM non-amyloidogenic rIAPP, used as a negative control
(Fig. 2B). Cell pre-treatment with 10 μM DPI and 100 μM Apo
[32–34] before exposure to 60 nM hIAPP aggregates resulted in
inhibition of basal and hIAPP-induced NADPH oxidase activity
(po0.001; Fig. 2C) thus confirming enzyme activation.
Nox1 and Nox4 protein expression and role of RAGE
To elucidate the mechanisms underlying the increase of NADPH
oxidase activity following cell exposure to hIAPP aggregates, we
focused on Nox4 and Nox1, the catalytic subunits expressed in this
cell line. No significant change in Nox4 protein expression, as
Fig. 1. Characterisation of hIAPP aggregates. TEM imaging of hIAPP aggregates
obtained after 30 min of incubation at 6.5 μM under aggregation conditions.
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assessed by western blot, was observed in hIAPP-treated cells
compared to vehicle-exposed cells (Fig. 3B). On the contrary, the
level of Nox1 expression was significantly increased in hIAPP-
treated cells (po0.01; Fig. 3A), suggesting that the increase of
NADPH oxidase activity is likely associated to that of Nox1
expression. It has previously been reported that amyloid aggre-
gates bind RAGE [35–37] and that receptor engagement by itself
can generate ROS in part via NADPH oxidase [38]. Therefore, we
checked the expression level of RAGE in hIAPP exposed cells and
found it was significantly increased with respect to vehicle
exposed cells (po0.01; Fig. 3C).
To assess whether the previously reported hIAPP-RAGE inter-
action [36,37] was actually involved in the observed increase of
both Nox1 expression and NADPH oxidase activity, we measured
such parameters in RIN-5F cells pre-treated with a blocking anti-
RAGE antibody before exposure to 60 nM hIAPP aggregates for
3.0 h. These cells displayed a significant decrease both in Nox1
expression (Fig. 4A) and in NADPH oxidase activity (Fig. 4B)
(po0.01 Vs hIAPP-treated cells). No significant change in both
Nox1 protein expression and NADPH oxidase activity was
observed when RIN-5F cells were treated with pre-immune non-
specific IgG before exposure to 60 nM hIAPP aggregates for 3.0 h
(data not shown). These data confirm the RAGE-hIAPP oligomer
interaction and suggest that it upregulates the expression of the
receptor itself and of Nox1 which, in turn, is responsible for the
increase of NADPH oxidase activity.
Enzymatic antioxidant defences and oxidative stress damage
In spite of the observed activation of NADPH oxidase, we did not
find a significant decrease of viability (assessed by MTT reduction
and LDH release assays) of the cells exposed for 3.0 h to 60 nM
hIAPP aggregates compared to vehicle-treated cells (data not
shown). These findings led us to hypothesise the occurrence of a
buffering effect provided by an increase of the antioxidant defences.
Therefore, we measured the activities of CAT and GPx, which
catalyse H2O2 decomposition, after 3.0 h of cell exposure to hIAPP
aggregates. Remarkably, CAT and GPx activities were significantly
higher in hIAPP-treated cells with respect to vehicle-exposed cells
(po0.01 CAT Vs vehicle-treated cells; po0.05 GPx Vs vehicle-
treated cells). Such an increase was completely abolished when the
cells were pre-incubated with DPI or with an anti-RAGE antibody
(Fig. 5A and C), while no effect was found in cells not exposed to
hIAPP. Moreover, an increase of the expression levels of the two
antioxidant enzymes was evident (Fig. 5B and D) that was not
present when the cells were pre-treated with DPI. These data
suggest a close relationship among the increase of the activities of
the two antioxidant enzymes and of NADPH oxidase via the hIAPP-
RAGE interaction supporting that, at our conditions, transcriptional
upregulation of CAT and GPx may be associated with the activation
of NADPH oxidase.
At variance with CAT and GPx, SOD activity was not signifi-
cantly modified at the same experimental conditions (hIAPP-
treated cells: 7.18 U/mg71.07; vehicle-treated cells: 7.17 U/mg7
1.23, N¼3).
This scenario agrees with the results of the analysis of ROS
levels in cells exposed for 3.0 h to 60 nM hIAPP: in spite of NADPH
oxidase activation, we did not find any significant increase of ROS
content in these cells, as compared to vehicle-treated cells
(Fig. 6A). To confirm that in hIAPP-exposed cells the reduced
oxidative stress in the presence of increased NADPH oxidase
activity did result from the activation of the two antioxidant
enzymes, we measured ROS levels in the same cells pre-treated
for 1.0 h with the CAT inhibitor ATZ (20 mM) or with the GPx
inhibitor MS (7.0 mM) and we found a significant increase of ROS
content (Fig. 6A), in agreement with previous data [12,14]. When
we assayed the level of oxidative stress in terms of lipoperoxida-
tion in hIAPP-exposed cells, we observed a significant decrease of
MDA content (Fig. 6B); on the other side, the level of MDA in cells
pre-incubated for 1.0 h with a mixture of 20 mM ATZ and 7.0 mM
MS before exposure to hIAPP aggregates was not significantly
different from that of vehicle-treated cells.
Fig. 2. NADPH oxidase activity increases in RIN-5F cells exposed to hIAPP
aggregates. NADPH oxidase activity in RIN-5F cells exposed to 60 nM hIAPP for 0.0,
1.5, 3.0, and 4.5 h (A); NADPH oxidase activity in RIN-5F cells exposed to 60, 120,
and 500 nM hIAPP, to 120 nM rIAPP or to vehicle for 3 h (B); NADPH oxidase
activity in RIN-5F cells pre-treated or not with 10 μM DPI or 100 μM Apo and then
exposed to 60 nM hIAPP or to vehicle for 3 h (C). Data are expressed as percentage
of maximum value for each experiment and presented as mean7SD. npo0.05,
nnpo0.01, and nnnpo0.001 Vs vehicle-treated cells; †po0.05, ††po0.01, and
†††po0.001 Vs hIAPP-treated cells. N¼8, separate experiments. hIAPP, human islet
amyloid polypeptide, rIAPP, non-amyloidogenic rodent IAPP. Yellow bars: vehicle-
treated cells; blue bars: hIAPP-treated cells. (For interpretation of the references to
color in this figure legend, the reader is referred to the web version of this article.)
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Taken together, these data suggest that the amount of ROS
produced by NADPH oxidase at these experimental conditions is
not harmful to cells but, rather, appears a protective response that
serves a signalling function resulting in increased anti-
oxidant power.
Discussion
The importance of hIAPP aggregation in type 2 diabetes patho-
genesis and the contribution of oxidative stress to hIAPP toxicity,
which plays a pivotal role in disease-associated cell dysfunction
Fig. 3. Nox1, Nox4 and RAGE expression after cell exposure to hIAPP aggregates. Nox1 (A), Nox4 (B) and RAGE (C) expression in RIN-5F cells exposed for 3 h to 60 nM
hIAPP or to vehicle. (Upper) Representative immunoblots out of three that gave qualitatively identical results. GAPDH was used to confirm equal protein loading. (Lower)
Densitometric quantifications of the Nox1, Nox4 or RAGE ratio to GAPDH protein expression. Data are expressed as percentage of maximum value for each experiment and
presented as mean7SD. nnpo0.01 Vs vehicle-treated cells. N¼3, separate experiments. Yellow bars: vehicle-treated cells; blue bars: hIAPP-treated cells. (For interpretation
of the references to color in this figure legend, the reader is referred to the web version of this article.)
Fig. 4. Effect of cell pre-incubation with anti-RAGE antibody on Nox1 protein expression and NADPH oxidase activity. Nox1 protein expression (A) and NADPH oxidase
activity (B) in RIN-5F cells pre-incubated or not with a specific anti-RAGE antibody and then exposed for 3 h to 60 nM hIAPP or to vehicle. (A): (Upper) Representative
immunoblot out of five that gave qualitatively identical results; GAPDH was used to confirm equal protein loading; (Lower) densitometric quantification of the Nox1 ratio to
GAPDH protein expression. Data are expressed as percentage of maximum value for each experiment and presented as mean7SD. npo0.05, nnpo0.01 Vs vehicle-treated
cells; ††po0.01 Vs hIAPP-treated cells. N¼5, separate experiments. Yellow bars: vehicle-treated cells; blue bars: hIAPP-exposed cells. (For interpretation of the references to
color in this figure legend, the reader is referred to the web version of this article.)
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and death, is generally accepted [10,12,39], although the details of
the phenomenon are still far from being defined. Previous
approaches to this problem used hIAPP concentrations (usually
in the 10–30 μM range), much higher than those experienced
physiologically by the cells in the pancreatic islets [12–14], so that
the resulting strong toxic insult could mask the subtle events
resulting from the presence of tiny amounts of amyloid aggregates.
In this study we hypothesised that cell treatment with low
concentrations of hIAPP aggregates for a short time period recalls
more closely the conditions present in the pancreas, particularly in
a pre-diabetic phase and at the onset of the pathology. Here we
show for the first time: (i) that exposure of pancreatic β-cells to a
low concentration of hIAPP amyloid aggregates for a short time
increases NADPH oxidase expression and activity; (ii) that such
activation depends on RAGE engagement by the aggregates; and
(iii) that RAGE-dependent NADPH oxidase activation triggers a
protective response through an increase of CAT and GPx expres-
sion and activity which counteracts ROS increase. We moved from
previous researches showing that different isoforms of NADPH
oxidase are expressed in rat islets and in pancreatic β-cells
[20,40,41], that they are increased in type 2 diabetes [11,40] and
seem to be involved in ROS generation and oxidative stress
associated to the pathology [12]. The involvement of NADPH
oxidase in the context of various stimuli eliciting oxidative stress
in pancreatic cells was indirectly suggested by protection provided
by the antioxidant Apo and by the flavoprotein inhibitor DPI,
two commonly used, yet not specific, NADPH oxidase inhibitors
[32–34].
Using 60 nM hIAPP aggregates we observed a transitory sig-
nificant increase in NADPH oxidase activity (by 50%) after 3.0 h
of cell exposure; this was associated to the increase of Nox1
expression (by 44%), in agreement with previous findings
showing that Nox1 is subjected to transcriptional regulation under
a variety of stimuli [42]. At variance of Nox1, Nox4 expression was
unchanged. Then, we investigated whether the increase of Nox1
expression induced by hIAPP aggregates was mediated by some
membrane component. It is known that amyloid aggregates,
besides interacting directly and non-specifically with the phos-
pholipid bilayer inducing membrane permeabilization and disrup-
tion [31], can also bind preferentially to a number of receptor-like
membrane proteins [43]. It is conceivable that at low aggregate
concentration such “ligand” behaviour may be prevalent with
respect to a more massive membrane disrupting effect. RAGE is
one of the most studied membrane proteins involved in amyloid
binding [35–37] and, in many cases, its activation by different
ligands can result in NADPH oxidase-dependent ROS production
[38]. Moreover, RAGE expression and activation are characteristic
hallmarks of diabetes [44,45]. Given that RAGE expression can be
increased by its ligands and by amyloid deposits, and that in BV-2
cells hIAPP aggregates bind RAGE with a Kd of about 68 nM
Fig. 5. Enzymatic antioxidant defences in RIN-5F cells exposed to hIAPP aggregates. CAT (A) and GPx (C) enzymatic activities in RIN-5F cells pre-incubated or not in the
presence of 10 μM DPI or of a specific anti-RAGE antibody before a 3 h exposure to 60 nM hIAPP aggregates or to vehicle. CAT (B) and GPx (D) protein expression in RIN-5F
cells pre-incubated or not with 10 μM DPI before exposure for 3 h to 60 nM hIAPP or to vehicle: (upper) representative immunoblots out of three that gave qualitatively
identical results, GAPDH was used to confirm equal protein loading; (lower) densitometric quantification of the CAT or GPx ratio to GAPDH protein expression. Data are
expressed as percentage of maximum value and presented as mean7SD. npo0.05, nnpo0.01, and nnnpo0.001 Vs vehicle-treated cells; †po0.05, ††po0.01, and †††po0.001
Vs hIAPP-exposed cells. N¼7 for (A) and (C); N¼3 for (B) and (D), separate experiments. Yellow bars, vehicle-treated cells; blue bars, hIAPP- treated cells. (For interpretation
of the references to color in this figure legend, the reader is referred to the web version of this article.)
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[37,46], we checked whether the same was true even at our
experimental conditions. Actually, we observed a significant
increase of RAGE level in cells exposed for 3.0 h to 60 nM hIAPP
aggregates that matched that of NADPH oxidase expression and
activity and was abrogated by pre-treatment with RAGE-blocking
antibodies, supporting the hypothesis that it depends on oligomer-
RAGE interaction.
Our novel finding was that hIAPP aggregate-mediated NADPH
oxidase activation (via RAGE) was not accompanied by a signifi-
cant build-up of ROS and the level of lipid peroxidation was even
significantly reduced, although the same hIAPP aggregates were
toxic when administered to cells for a longer time period (24 h)
[21]. These data were quite unexpected, considering that oxidative
stress is a shared biochemical modification in cells exposed to
toxic amyloids [7,47], and that pancreatic β-cells in general,
particularly RIN-5F cells, are reported to possess scarce antioxidant
defences [8,9,48]. An explanation of our surprising results came
from the analysis of the enzymatic antioxidant defences of the
cells at our experimental conditions. In fact, in oligomer-exposed
cells we observed a significant up regulation of CAT and GPx
activities, similar to that previously reported in other biological
systems following NADPH oxidase activation [26,49]. In our
experimental model CAT and GPx activity upregulation matched
a parallel increase of their expression. At this stage our knowledge
of the mechanism by which the observed upregulation of protein
expression does occur is incomplete; however, we showed it was
dependent on both RAGE engagement and NADPH oxidase activa-
tion, since it was abrogated by cell pre-treatment with either
blocking anti-RAGE antibodies or DPI. Accordingly, a signalling role
of NADPH oxidase-mediated ROS production can be hypothesised.
In fact, among ROS producing systems, NADPH oxidases may be
considered unique in that they generate ROS in a highly regulated
manner, whereas all other enzymatic sources generate ROS as a
by-product of the enzyme activity [17,50]. Our results extend
previous findings obtained in other cells (cardiomyocytes, cancer
cells) supporting the beneficial effects of low/moderate concen-
trations of ROS, that can be seen as a hormetic stimulus [50,51].
Hormesis can be defined as the phenomenon by which a stressor
which is toxic at high doses, at low doses becomes protective by
stimulating cell defence responses. Our data suggest that the
response of our β-cell model to low amounts of hIAPP aggregates
present for short time periods displays at least some features of
hormesis. In fact, while high doses of hIAPP aggregates (10–
30 μM) inhibit antioxidant enzyme activity and are toxic to the
exposed cells also by increasing the oxidative stress to unsustain-
able levels [12,14], low doses of hIAPP aggregates administered for
a limited time period to the cells may turn out to be protective by
upregulating the activity of the same antioxidant enzymes and
reducing the extent of lipoperoxidation.
Growing interest is being paid to hormesis in the context of
amyloid diseases. For example, it has been observed that Aβ
amyloid aggregates, whose accumulation in the brain is consid-
ered one of the main hallmarks of Alzheimer's disease, when
infused in the mouse hippocampus at picomolar-low nanomolar
level increase acetylcholine production [52,53] stimulate long-
term potentiation and improve cognitive performance [53]. Simi-
larly, non-harmful levels of ER stress following moderate exposure
to amyloid aggregates protect against experimental Parkinson
disease [54]. Finally, for what type 2 diabetes is concerned,
hormesis has been evoked to explain the resistance of some
subjects to diabetes-promoting lifestyle factors [55], the anti-
diabetic effect of physical exercise [56] and, in general, the variable
rates of β-cell deterioration along the transition from the adaptive/
compensatory stage to the terminal, severely decompensated,
phase of the disease.
Our findings provide new insights into the pathophysiological
processes involved in the development of type 2 diabetes support-
ing that, in the pre-diabetic compensatory phase, a low concen-
tration of hIAPP amyloid aggregates may enhance the enzymatic
antioxidant defences through a RAGE-Nox1-mediated pathway.
Anyway, due to the multifactorial character of type 2 diabetes, care
should be taken in the interpretation of these results. A recent
review has outlined the protective role of mild oxidative stress
during the early stages of type 2 diabetes, focusing on the
production of 4-hydroxyalkenals (a by-product of lipid peroxida-
tion) as an hormetic factor [57]. A low dose of 4-hydroxyalkenals
would promote several protective responses, among which the
increased expression of antioxidant enzymes via the Nrf 2 tran-
scription factor [58], and the upregulation of insulin secretion via
the activation of PPARδ [57]. This hormetic response could be
counteracted by the one that we describe, since low doses of hIAPP
aggregates reduce lipid peroxidation in the case the two phenom-
ena are contemporary, whereas the two hormetic responses could
vicariate each other if they occur sequentially during the devel-
opment of the disease. This matter deserves further investigation
in models closely mimicking the complexity of the disease.
Our results shed new light on the reported presence of hIAPP
aggregates also in non-diabetic human pancreas [59] and suggest
that care should be taken when thinking of an anti-amyloid
therapy for the prevention of type 2 diabetes, as this could
Fig. 6. ROS level and lipid peroxidation in RIN-5F cells exposed to hIAPP
aggregates. ROS level (A) and lipid peroxidation, assessed as MDA content (B) in
RIN-5F cells pre-treated or not for 1 h with 20 mM ATZ and 7.0 mMMS before a 3 h
exposure to 60 nM hIAPP or to vehicle. Data are expressed as percentage of
maximum value for each experiment and presented as mean7SD. npo0.05,
nnpo0.01 Vs vehicle-treated cells; †po0.05 Vs hIAPP-treated cells. N¼5, separate
experiments. Yellow bars, vehicle-treated cells; blue bars, hIAPP-treated cells.
(For interpretation of the references to color in this figure legend, the reader is
referred to the web version of this article.)
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paradoxically speed up the progression of the disease. On the
other side, such an approach could be appropriate when the
disease has entered the decompensation phase, when the accu-
mulation of toxic amyloid species, in addition to other diabetes-
promoting factors, may overwhelm the hormetic effect resulting in
a failure of the cellular defences with progression towards type
2 diabetes.
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